These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1830 related articles for article (PubMed ID: 26841800)

  • 1. Psychedelics.
    Nichols DE
    Pharmacol Rev; 2016 Apr; 68(2):264-355. PubMed ID: 26841800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hallucinogens.
    Nichols DE
    Pharmacol Ther; 2004 Feb; 101(2):131-81. PubMed ID: 14761703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular safety of psychedelic medicine: current status and future directions.
    Wsół A
    Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of serotonergic psychedelics.
    Hanks JB; González-Maeso J
    ACS Chem Neurosci; 2013 Jan; 4(1):33-42. PubMed ID: 23336043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psilocybin and Other Classic Psychedelics in Depression.
    Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D
    Curr Top Behav Neurosci; 2024; 66():149-174. PubMed ID: 37955822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics as Medicines: An Emerging New Paradigm.
    Nichols DE; Johnson MW; Nichols CD
    Clin Pharmacol Ther; 2017 Feb; 101(2):209-219. PubMed ID: 28019026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal Behavior in Psychedelic Research.
    Odland AU; Kristensen JL; Andreasen JT
    Pharmacol Rev; 2022 Oct; 74(4):1176-1205. PubMed ID: 36180111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
    Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E
    Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape.
    Singleton SP; Luppi AI; Carhart-Harris RL; Cruzat J; Roseman L; Nutt DJ; Deco G; Kringelbach ML; Stamatakis EA; Kuceyeski A
    Nat Commun; 2022 Oct; 13(1):5812. PubMed ID: 36192411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
    Preller KH; Burt JB; Ji JL; Schleifer CH; Adkinson BD; Stämpfli P; Seifritz E; Repovs G; Krystal JH; Murray JD; Vollenweider FX; Anticevic A
    Elife; 2018 Oct; 7():. PubMed ID: 30355445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.
    Canal CE
    Handb Exp Pharmacol; 2018; 252():227-260. PubMed ID: 29532180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelics and schizophrenia.
    González-Maeso J; Sealfon SC
    Trends Neurosci; 2009 Apr; 32(4):225-32. PubMed ID: 19269047
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 92.